Encourages Regulators and Lawmakers to Expose Additional Egregious Examples of Anti-Competitive Behavior

(Washington, D.C.) — The Public Innovation Project (PIP) released the following statement on the Federal Trade Commission’s (FTC) filing of an amicus brief, Teva Branded Pharmaceutical Products R&D, et al. v. Amneal Pharmaceuticals of New York, LLC, et al., on Big Pharma company Teva Pharmaceuticals’ invalid patent listings on inhaler products.

“Public Innovation Project applauds the FTC for building on its commitment to cracking down on invalid patents in the Orange Book and exposing Big Pharma’s monopolistic anti-competitive tactics that undermine true innovation and keep prices high for consumers,” said PIP executive director Joshua Lamel. “Too often, Big Pharma companies, like Teva Pharmaceuticals, get away with egregious anti-competitive gamesmanship of the patent system to keep would-be competitors out of the marketplace.”

“As the FTC cracks down on Big Pharma’s rampant patent abuse, especially with inhaled products, we urge regulators to expose additional egregious examples and lawmakers to advance legislative solutions to support greater competition and innovation in the pharmaceutical marketplace.”

In addition to filing the amicus brief on Teva’s patent listings, the FTC previously sent letters to several drug companies that have improperly listed patents.

Read more on legislative solutions to address Big Pharma’s patent abuse HERE.

Find out more about PIP and our mission HERE.

###